The Scientific World Journal

Development of Radiolabeled Compounds for Molecular Imaging and Imaging-Based Therapy

Publishing date
05 Sep 2014
Submission deadline
27 Jun 2014

Lead Editor

1Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan

2Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan

3Department of Nuclear Medicine and Medical PET Center, The Second Hospital of Zhejiang University School of Medicine, Zhejiang, China

4Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan

5Molecular and Cellular Imaging, Comprehensive Heart Failure Center, Universitätsklinikum Würzburg, Würzburg, Germany

Development of Radiolabeled Compounds for Molecular Imaging and Imaging-Based Therapy


In recent years, a companion diagnosis for prediction of the effectiveness and the side effects after administration of drugs has become very important to decide a therapeutic strategy. In USA, Food and Drug Administration (FDA) recommends the development of the companion diagnostic agent simultaneously with a new drug development. Nuclear Medicine Imaging using positron emission tomography (PET) or single photon emission computed tomography (SPECT), which visualizes target molecules, is able to detect biological and biochemical changes in the earlier phases of diseases differing from an anatomical imaging using X-ray computed tomography (X-ray CT) or magnetic resonance imaging (MRI). Radiolabeled tracers for the nuclear medicine have great potential to provide a lot of information about pathology of individual patients depending on characteristics of each tracer and could be the companion diagnostics. Accordingly, molecular imaging and imaging-based therapy using radiolabeled tracers must contribute to the realization of personalized medicine.

We are interested in research articles as well as review articles about development and usefulness of radiolabeled compounds for molecular imaging and imaging-based therapy. Potential topics include, but are not limited to:

  • Radiolabeled compounds for early detection of therapeutic effects
  • Hypoxia imaging
  • Predicting therapeutic effect of molecular targeted anticancer drugs
  • Receptor imaging and evaluation of receptor occupancy
  • Bone disorder imaging
  • Diagonosis of Alzheimer's disease
  • Imaging of atherosclerotic plaques
  • Quantification of blood flow and metabolism
  • Imaging of inflammatory disorders

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

The Scientific World Journal
 Journal metrics
Acceptance rate24%
Submission to final decision68 days
Acceptance to publication29 days
Journal Citation Indicator-
Impact Factor-

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.